FDA Says Allergan Aczone Ads Were Misleading

The U.S. Food and Drug Administration on Friday released a letter to Allergan Inc. saying that the company’s marketing and advertising efforts for Aczone, an acne treatment, are misleading.

The letter, addressed to Allergan Chief Executive David E.I. Pyott, states Aczone’s effectiveness is overstated and that risk factors associated with the drug are omitted from a print advertisement.

Read full story via bizjournals:.

Short URL: http://www.plasticsurgeonsnews.com/?p=382

Posted by admin on Aug 22 2009. Filed under Injectables, Marketing. You can follow any responses to this entry through the RSS 2.0. You can leave a response or trackback to this entry